Genomind is a unique personalized medicine platform that brings innovation to healthcare around the world. Genomind, comprised of pioneering scientists and thought leaders in brain health and genetics, delivers actionable insights to clinicians, healthcare partners and individuals in order to improve the quality of human life.
Genomind is a registered laboratory in the United States Founded in 2009 by Dr. Ronald Dozoretz with the vision of bringing personalized medicine to neuropsychiatry. Its mission is to improve the lives of patients with mental illness by bringing innovative technologies to clinical care. Genomind’s core service is a pharmacogenetic test called the Genecept Assay.
Genecept Assay is designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, more likely to cause adverse effects and what doses may be optimal. Genecept covers more than fifteen drug classes, 120 FDA-approved medications, eighteen clinically-validated genes and 97% of medications used to treat depression, anxiety, bipolar disorder, schizophrenia, attention deficit disorder and autism. It also offers a comprehensive coverage of pain medications. While Genecept is useful for improving psychiatric outcomes, the inclusion of 6 CYP450 genes makes it universally applicable in enhancing dosing guidance for all drug classes, such as cardiovascular or endocrine medications.